A Study of YL242 in Subjects With Advanced Solid Tumors
Phase 1/2
424
about 3.2 years
18+
7 sites in CT, FL, MA +3
What this study is about
Researchers are testing the safety and tolerability of YL242, either alone or with other medications like 5-FU or Pembrolizumab, in people with advanced solid tumors. The trial will last for about a year and a half.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take YL242
- 2.Take YL242; 5-FU; LV
- 3.Take YL242; Pembrolizumab
- +1 more
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
pembrolizumab (Immune checkpoint inhibitor; blocks PD-1 to boost T-cell attack on cancer), immunotherapy (Immune checkpoint inhibitor; blocks PD-1 to boost T-cell attack on cancer)
infusion
Primary: Number of Participants Reporting Treatment-emergent Adverse Events (TEAEs), Objective Response Rate (ORR) in Participants With Advanced Solid Malignant Tumors (Part 2, and 4-6)
Secondary: Area Under the Serum Concentration Time Curve (AUC) of YL242, Disease Control Rate (DCR), Maximum Plasma Concentration (Cmax) of YL242, Terminal Elimination Half-life (t1/2) of Serum YL242, Time to Maximum Plasma Concentration (Tmax) of YL242
Oncology